As a potent inhibitor against Abl, c-kit, PDGFRβ and, in particular, Src and EphA2, which have been shown to play important roles in prostatic tumorigenesis [13,14], dasatinib holds high promise as a potential treatment for prostate cancer. Here, SRC is linked to prostate carcinoma.